SALVAT grants license to Korean firm Kwang-Dong Pharmaceutical for urinary incontinence treatment
Overactive bladder is one of the most common pathologies among elderly Koreans. The market for treatment has grown more than 15% annually in the past few years.
Catalan biopharmaceutical company Laboratorios SALVAT has granted a license to Korean company Kwang Dong Pharmaceutical Co LTD for developing, registering and marketing Tarafenacin, a drug for treating overactive bladder syndrome, in South Korea. The drug has already completed Phase II clinical trials. According to SALVAT, at each stage of clinical development the drug has shown excellent results for efficacy and tolerability.
Kwang Dong is one of the principal Korean pharma companies and has broad experience in developing drugs in late-stage clinical development and subsequently introducing them into the Korean market, chiefly in the areas of cancer and quality of life.
Overactive bladder is one of the most common maladies facing seniors. In the past few years in Korea the market for treatment has expanded by more than 15% annually. “However, it still represents an unmet medical need in terms of efficacy and performance,” explained Sung Won Choi, president of Kwang Dong. Kwang Dong believes that Salvat’s drug has major potential for success and for meeting unanswered therapeutic demands, such as minimizing side effects.
“We are very satisfied with having established long term relations with Kwang Dong, and this accord is the first step in our strategy to license out Tarafenacin for development and marketing around the world,” stated SALVAT president Javier Peris.
Salvat grants license to Korean firm Kwang-Dong Pharmaceutical for urinary incontinence treatment
Overactive bladder is one of the most common pathologies among elderly Koreans. The market for treatment has grown more than 15% annually in the past few years.
24.11.2010
Catalan biopharmaceutical company Laboratorios Salvat has granted a license to Korean company Kwang Dong Pharmaceutical Co LTD for developing, registering and marketing Tarafenacin, a drug for treating overactive bladder syndrome, in South Korea. The drug has already completed Phase III clinical trials. According to Salvat, at each stage of clinical development the drug has shown excellent results for efficacy and tolerability.
Kwang Dong is one of the principal Korean pharma companies and has broad experience in developing drugs in late-stage clinical development and subsequently introducing them into the Korean market, chiefly in the areas of cancer and quality of life.
Overactive bladder is one of the most common maladies facing seniors. In the past few years in Korea the market for treatment has expanded by more than 15% annually. “However, it still represents an unmet medical need in terms of efficacy and performance,” explained Sung Won Choi, president of Kwang Dong. Kwang Dong believes that Salvat’s drug has major potential for success and for meeting unanswered therapeutic demands, such as minimizing side effects.
“We are very satisfied with having established long term relations with Kwang Dong, and this accord is the first step in our strategy to license out Tarafenacin for development and marketing around the world,” stated Salvat president Javier Peris.
PEU DE FIGURA: Javier Peris, president of Salvat, and Sung Won Choi, president of Kwang Dong (Photo: © Salvat)